Finally, this combination was effective in one EGFR-mutated patient with MET amplification at our local hospital, Montpellier Cancer Institute, and fits with a very recent clinical trial showing that the combination of osimertinib and a MET inhibitor (savolitinib) has a therapeutic effect in patients with EGFR-mutated and MET-amplified lung cancer following relapse after osimertinib [5], further validating the EGFR/MET mouse as a preclinical model mimicking the human disease. The gene discussed is EGFR; the disease is lung carcinoma.